Manu Sebastian
PROFESSOR
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (6)
Drug repurposing is the process of reusing existing pharmaceuticals for novel clinical purposes, which offers advantages such as streamlined clinical trial access and reduced drug development costs. Clarithromycin (CAM), a member of the macrolide antibiotics family, is a promising candidate for repurposing in cancer therapy due to its known preclinical and clinical immunomodulatory and anticancer properties. In the current study, we investigated whether CAM could be repurposed as a preventive treatment for KRAS-mutant lung cancer, a subtype of lung adenocarcinoma that is strongly associated with heavy smoking. CCSPCre; LSL-KrasG12D mice at an early stage of tumor development were treated with different doses of CAM for 10 weeks. While exhibiting an excellent safety profile, CAM was able to prevent the development of premalignant and malignant lung lesions in a dose-dependent manner. In addition, CAM significantly reduced the infiltration of neutrophils/polymorphonuclear myeloid-derived suppressor cells and inhibited the mRNA expression of protumor inflammatory cytokines IL-6, TNFα, and IL-1β, as well as M2 macrophage markers Fizz1 and Arginase1 in the lung tumor microenvironment. Moreover, we investigated the effect of CAM in reshaping the intestinal and lung microbiome. Long-term CAM usage decreased intestinal microbiome diversity but, more notably, significantly increased the abundance of the probiotic genus Muribaculaceae while decreasing the abundance of Desulfovibrio, a genus associated with the promotion of various malignancies. Taken together, we conclude that CAM could provide promising cancer prevention efficacy in KRAS-mutant lung cancer due to its immunomodulatory properties on the tumor microenvironment and its regulatory effects on the microbiome.
Year:
2026
Supplementary figures and legends showing CAM effect on organ weight and blood chemistry analysis; survival study of CAM supplemented in chow diet; IHC staining of proliferation, apoptosis and angiogenesis; CAM treatment effect on lung microbiome.
Year:
2026
Drug repurposing is the process of reusing existing pharmaceuticals for novel clinical purposes, which offers advantages such as streamlined clinical trial access and reduced drug development costs. Clarithromycin (CAM), a member of the macrolide antibiotics family, is a promising candidate for repurposing in cancer therapy due to its known preclinical and clinical immunomodulatory and anticancer properties. In the current study, we investigated whether CAM could be repurposed as a preventive treatment for KRAS -mutant lung cancer, a subtype of lung adenocarcinoma that is strongly associated with heavy smoking. CCSP Cre ; LSL-Kras G12D mice at an early stage of tumor development were treated with different doses of CAM for 10 weeks. While exhibiting an excellent safety profile, CAM was able to prevent the development of premalignant and malignant lung lesions in a dose-dependent manner. In addition, CAM significantly reduced the infiltration of neutrophils/polymorphonuclear myeloid-derived suppressor cells and inhibited the mRNA expression of protumor inflammatory cytokines IL-6, TNFα, and IL-1β, as well as M2 macrophage markers Fizz1 and Arginase1 in the lung tumor microenvironment. Moreover, we investigated the effect of CAM in reshaping the intestinal and lung microbiome. Long-term CAM usage decreased intestinal microbiome diversity but, more notably, significantly increased the abundance of the probiotic genus Muribaculaceae while decreasing the abundance of Desulfovibrio , a genus associated with the promotion of various malignancies. Taken together, we conclude that CAM could provide promising cancer prevention efficacy in KRAS -mutant lung cancer due to its immunomodulatory properties on the tumor microenvironment and its regulatory effects on the microbiome.
Year:
2026
Toxicologic pathologists assess large data sets from nonclinical studies to identify treatment-related effects to assist in predicting human safety hazards. Statistical testing can facilitate data interpretation by highlighting group differences that have a low probability of random occurrence based on a pre-determined P -value cut-off (eg, P < .05). While this method has been used in the interpretation of pathology data for decades, the appropriateness of utilizing statistical testing in this way has been challenged. Here, we discuss common statistical pitfalls in the analysis of toxicologic pathology data, with emphasis on clinical pathology, reaffirming that appropriate use of statistical analysis requires an understanding of (1) the parameters assessed; (2) the inherent strengths and weaknesses of the statistical method used; and (3) that appropriate interpretation of pathology data is based on the pathologist’s expertise. The presence or absence of statistical significance should not supersede expert judgment but should be one of many tools used to reach a conclusion.
Year:
2025
Loss-of-function mutations in autophagy-related (ATG) genes are rare in cancer. However, we report herein that ATG5 is fully deleted in ∼14% of prostate cancers (PCa), rivaling that of well-established tumor suppressor genes. ATG5 expression was downregulated at both mRNA and protein levels and was associated with poor patient survival. The DU145 PCa cell line, isolated from a brain metastasis, is entirely deficient in ATG5; and while ATG5 reintroduction restored autophagy, it dramatically inhibited tumor growth in vivo and led to near complete consumption of the multifunctional autophagy receptor/signaling protein, p62. Deletion of SQSTM1 confirmed that p62 was essential for tumor growth; and Reverse Phase Protein Array analysis revealed that p62 protein was significantly increased in prostate tumors, despite a reduction in mRNA expression. Thus, ATG5 appears to function as a novel tumor suppressor in a subset of prostate tumors and does so, at least in part, through autophagic degradation of p62.
Year:
2025
Mutations in KRAS are found in more than 50% of tumors from patients with metastatic colorectal cancer (mCRC). However, direct targeting of most KRAS mutations is difficult; even the recently developed KRASG12C inhibitors failed to show significant benefit in patients with mCRC. Single agents targeting MEK, a downstream mediator of RAS, have also been ineffective in CRC. To identify drugs that can enhance the efficacy of MEK inhibitors we performed unbiased high-throughput screening using CRC spheroids. We used trametinib as the anchor drug and examined combinations of trametinib with the National Cancer Institute Approved Oncology Library version 5. The initial screen, and following focused validation screens, identified vincristine as being strongly synergistic with trametinib. In vitro, the combination strongly inhibited cell growth, reduced clonogenic survival, and enhanced apoptosis compared to monotherapies in multiple KRAS-mutant CRC cell lines. Furthermore, this combination significantly inhibited tumor growth, reduced cell proliferation, and increased apoptosis in multiple KRAS-mutant patient-derived xenograft mouse models. In vivo studies using drug doses that reflect clinically achievable doses demonstrated that the combination was well tolerated by mice. We further determined that the mechanism underlying the synergistic effect of the combination was due to enhanced intracellular accumulation of vincristine associated with MEK inhibition. The combination also significantly decreased p-mTOR levels in vitro, indicating that it inhibits both RAS-RAF-MEK and PI3K-AKT-mTOR survival pathways. Our data thus provide strong evidence that the combination of trametinib and vincristine represents a novel therapeutic option to be studied in clinical trials for patients with KRAS-mutant mCRC.
Year:
2024
Collaborators (14)
Janos Roszik
The University of Texas MD Anderson Cancer Center
Scott E. Kopetz
The University of Texas MD Anderson Cancer Center
Dean Tang
Distinguished Professor & Chairperson
Roswell Park Comprehensive Cancer Center
Florencia McAllister
The University of Texas MD Anderson Cancer Center
Clifford Stephan
Research Associate Professor
Texas A&M University Health Sciences Center
C. Marcelo Aldaz
Professor
The University of Texas MD Anderson Cancer Center
Reid T Powell
Assistant Professor
Texas A&M University
Xiaozhuo Liu
Research Associate
Roswell Park Comprehensive Cancer Center
Shawn Bratton
Associate Professor
The University of Texas MD Anderson Cancer Center
Thais Bartelli
Research Investigator
The University of Texas MD Anderson Cancer Center
Seyed Javad Moghaddam
Professor
The University of Texas MD Anderson Cancer Center
Humam Kadara
The University of Texas MD Anderson Cancer Center
Powel Brown
Professor and Chairman
The University of Texas MD Anderson Cancer Center
Rajat Bhattacharya
Associate Professor
Baylor College of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.